- €50.59bn
- €45.99bn
- $4.15bn
Brief: Argenx Announces FDA Approval Of Vyvgart Hytrulo Prefilled Syringe For Self-Injection In Generalized Myasthenia Gravis And Chronic Inflammatory Demyelinating Polyneuropathy
US FDA approves syringe version of Argenx's immune disorder drug
European healthcare drops as Trump says tariffs on sector coming soon
European healthcare drops as Trump says tariffs on sector coming soon
Street View: Immunovant's muscle drug shows potential as analysts await data on lead candidate
Immunovant falls after UBS says late-stage data for muscle disorder drug 'underwhelms'
Bernstein ups ArgenX on growth prospects driven by Vyvgart
Brief: Argenx Publishes Long-Term Data At The American Academy Of Neurology 2025 Annual Meeting
Brief: Argenx: $737 Million In Q4 Global Product Net Sales
Brief: Argenx Q4 Net Income USD 774.161 Million
Barclays cautious on European pharma in H1, sees re-rating chance in H2
Brief: Argenx Reports $2.2 Bln FY Preliminary Global Product Net Sales
Altered states will rule in 2025: podcast
Brief: Argenx Announces Approval Of VYVDURA In Japan
Obesity giants will begin $80 bln M&A face-off
Obesity giants will begin $80 bln M&A face-off
Europe Research Roundup: Covivio, Mercedes-Benz Group, Persimmon
ArgenX tops BEL 20 on 'blue-sky scenario' Vyvgart progress
Brief: ArgenX: Phase 2 Data Establish Proof-Of-Concept Of Efgartigimod